MYX Stock Overview
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Mayne Pharma Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.83 |
| 52 Week High | AU$8.50 |
| 52 Week Low | AU$0.22 |
| Beta | 0.86 |
| 1 Month Change | -32.62% |
| 3 Month Change | -49.46% |
| 1 Year Change | -49.46% |
| 3 Year Change | -66.31% |
| 5 Year Change | -79.19% |
| Change since IPO | -76.42% |
Recent News & Updates
Recent updates
Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers
Dec 03
Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?
Dec 01Is Mayne Pharma Group (ASX:MYX) A Risky Investment?
Apr 12Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade
Mar 01We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope
Nov 16Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt
Nov 10Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt
May 17Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?
Mar 22How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?
Mar 01What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition
Feb 08Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit
Jan 18Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares
Dec 27Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?
Dec 09
A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation
Nov 24Shareholder Returns
| MYX | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -6.3% | -1.0% | 0.5% |
| 1Y | -49.5% | -28.9% | 1.8% |
Return vs Industry: MYX underperformed the Australian Pharmaceuticals industry which returned -28.9% over the past year.
Return vs Market: MYX underperformed the Australian Market which returned 1.8% over the past year.
Price Volatility
| MYX volatility | |
|---|---|
| MYX Average Weekly Movement | 9.6% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in AU Market | 15.5% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: MYX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: MYX's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Shawn O’Brien | https://www.maynepharma.com |
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.
Mayne Pharma Group Limited Fundamentals Summary
| MYX fundamental statistics | |
|---|---|
| Market Cap | AU$242.75m |
| Earnings (TTM) | -AU$263.34m |
| Revenue (TTM) | AU$424.80m |
0.6x
P/S Ratio-0.9x
P/E RatioIs MYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYX income statement (TTM) | |
|---|---|
| Revenue | AU$424.80m |
| Cost of Revenue | AU$253.77m |
| Gross Profit | AU$171.03m |
| Other Expenses | AU$434.37m |
| Earnings | -AU$263.34m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Feb 23, 2023
| Earnings per share (EPS) | -3.07 |
| Gross Margin | 40.26% |
| Net Profit Margin | -61.99% |
| Debt/Equity Ratio | 72.8% |
How did MYX perform over the long term?
See historical performance and comparison